EAGAN, MN, United States
EAGAN, MN, United States

Time filter

Source Type

This disclosure relates to the combination of soluble -glucan and immune suppression-relieving agents that affect the tumor microenvironment. Soluble -glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-angiogenics, checkpoint inhibitors including non-tumor targeting antibodies.


The present invention relates to the combination of soluble -glucan and anti-cancer agents that affect the tumor microenvironment. Soluble -glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.


The present invention relates to yeast cell wall 5 compositions enriched with mannose, mannose extracts and processes for making the same.


The present invention relates to the combination of soluble -glucan and anti-cancer agents that affect the tumor microenvironment. Soluble -glucan promotes an immunostimulatory environment, which allows enhanced effectiveness of anti-cancer agents.


Patent
Biothera | Date: 2014-11-04

The present invention relates to a process for decreasing off-flavors of dried beta glucan. The pH of the beta glucan is lowered prior to drying the beta glucan in order to reduce Maillard reactions which produce the off-flavors.


Patent
Biothera | Date: 2013-03-14

This disclosure describes, in one aspect, a composition that includes a -glucan component and an antibody component that specifically binds to the -glucan. In another aspect, this disclosure describes a method of increasing a subjects response to -glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of -glucan and administering to the subject a composition that comprises a -glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 149.45K | Year: 2014

DESCRIPTION (provided by applicant): Fungal infections, particularly in immunocompromised patients, are a serious and growing problem. Although antifungal therapeutics have improved greatly, failures and relapse are common. Aspergillus fumigatus is a primary cause of these infections in several patient populations: transplants, leukemics, genetic deficiencies such as chronic granulomatous disease and others, with mortality remaining high. Preventative antifungal vaccines are an attractive, but as yet unrealized, option. The goal of this proposal is to develop a prototype glucan-protein vaccine by conjugating a protein to a particulate -glucan immunomodulator (i.e., WGP), a cell wall component of many pathogenic fungi. Preliminary work using WGP alone or conjugated to a non-specific protein, bovine serum albumin (BSA), indicated that a glucan-protein vaccine was active against Aspergillus and Coccidioides. The work described in this proposal will examine the potential of conjugating a specific, immunodom


Patent
Biothera | Date: 2014-12-01

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subjects immune response to -glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti--glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti--glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti--glucan antibody.


Studies involving placebo-controlled, double-blinded designs to evaluate the effect of beta-glucan compositions on upper-respiratory tract infections and psychological wellness were carried out. During the course of the reporting periods of these studies, subjects in the treatment groups reported fewer URTI symptoms, better overall health and a more positive psychological assessment based on a POMS survey.


Patent
Biothera | Date: 2013-04-24

Particulate -glucan is solubilized at elevated pressure and temperature to form particulate-soluble -glucan. The particulate-soluble -glucan is capable of being dried to a powder form and subsequently re-solubilized.

Loading Biothera collaborators
Loading Biothera collaborators